Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Friday, down -3.41% from the previous trading day, before settling in for the closing price of $9.09. Over the past 52 weeks, PHAT has traded in a range of $6.07-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -38.36%. With a float of $36.70 million, this company’s outstanding shares have now reached $57.97 million.
Considering the fact that the conglomerate employs 452 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.07%, while institutional ownership is 69.14%. The most recent insider transaction that took place on Jul 15 ’24, was worth 127,760. In this transaction Chief Operating Officer of this company sold 10,901 shares at a rate of $11.72, taking the stock ownership to the 240,421 shares. Before that another transaction happened on Jul 15 ’24, when Company’s CFO and CBO sold 4,325 for $11.72, making the entire transaction worth $50,689. This insider now owns 99,447 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.8 earnings per share (EPS), higher than consensus estimate (set at -1) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.36% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach -4.10 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Compared to the last year’s volume of 0.9 million, its volume of 4.4 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 3.97%. Additionally, its Average True Range was 1.55.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 2.15%, which indicates a significant decrease from 2.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 164.31% in the past 14 days, which was higher than the 91.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.58, while its 200-day Moving Average is $12.14. Nevertheless, the first resistance level for the watch stands at $9.21 in the near term. At $9.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.97. If the price goes on to break the first support level at $8.45, it is likely to go to the next support level at $8.11. Should the price break the second support level, the third support level stands at $7.69.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 579.88 million has total of 68,377K Shares Outstanding. Its annual sales at the moment are 680 K in contrast with the sum of -201,590 K annual income. Company’s last quarter sales were recorded 16,350 K and last quarter income was -85,580 K.
